X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1180) 1180
female (724) 724
male (569) 569
adult (479) 479
index medicus (450) 450
leuprolide - therapeutic use (444) 444
leuprolide - adverse effects (427) 427
obstetrics & gynecology (387) 387
leuprolide (375) 375
prostatic neoplasms - drug therapy (362) 362
middle aged (356) 356
leuprolide - administration & dosage (319) 319
leuprolide acetate (318) 318
aged (310) 310
gonadotropin-releasing hormone - agonists (246) 246
prostate cancer (244) 244
antineoplastic agents, hormonal - therapeutic use (219) 219
antineoplastic agents, hormonal - adverse effects (218) 218
urology & nephrology (210) 210
treatment outcome (208) 208
gonadotropin-releasing hormone - analogs & derivatives (197) 197
aged, 80 and over (159) 159
endometriosis (159) 159
reproductive biology (158) 158
care and treatment (157) 157
pregnancy (155) 155
women (145) 145
antineoplastic agents, hormonal - administration & dosage (143) 143
cancer (138) 138
oncology (137) 137
prospective studies (137) 137
delayed-action preparations (136) 136
endometriosis - drug therapy (136) 136
testosterone - blood (135) 135
testosterone (128) 128
gonadotropin-releasing hormone - therapeutic use (122) 122
therapy (122) 122
animals (117) 117
androgen antagonists - therapeutic use (116) 116
estradiol - blood (113) 113
luteinizing hormone - blood (112) 112
retrospective studies (112) 112
prostatic neoplasms - pathology (111) 111
carcinoma (105) 105
endocrinology & metabolism (105) 105
gnrh agonist (102) 102
leuprolide - pharmacology (101) 101
gonadotropin-releasing hormone - adverse effects (99) 99
leiomyoma - drug therapy (98) 98
hormones (96) 96
time factors (95) 95
uterine neoplasms - drug therapy (94) 94
fertilization in vitro (92) 92
prostate-specific antigen - blood (92) 92
gonadotropin-releasing hormone - antagonists & inhibitors (91) 91
prostatic neoplasms - blood (91) 91
obstetrics and gynecology (85) 85
pharmacology & pharmacy (85) 85
drug administration schedule (82) 82
androgen antagonists - adverse effects (79) 79
men (78) 78
adolescent (76) 76
double-blind (76) 76
follicle stimulating hormone - blood (76) 76
estrogen (75) 75
gonadotropin-releasing-hormone (75) 75
double-blind method (73) 73
pituitary hormones (73) 73
research (73) 73
drug therapy, combination (71) 71
invitro fertilization (71) 71
drug therapy (69) 69
health aspects (69) 69
medicine, general & internal (68) 68
suppression (68) 68
adenocarcinoma - drug therapy (67) 67
analysis (67) 67
hormone agonist (67) 67
follow-up studies (66) 66
internal medicine (64) 64
progesterone - blood (64) 64
trial (64) 64
gonadotropin-releasing hormone - administration & dosage (62) 62
luteinizing-hormone (61) 61
quality of life (59) 59
child (58) 58
combined modality therapy (58) 58
risk factors (58) 58
surgery (58) 58
androgen antagonists - administration & dosage (57) 57
androgens (57) 57
embryo transfer (57) 57
goserelin - therapeutic use (57) 57
progesterone (57) 57
injections, subcutaneous (56) 56
medicine & public health (56) 56
antineoplastic combined chemotherapy protocols - therapeutic use (55) 55
pregnancy rate (55) 55
bone density - drug effects (54) 54
goserelin - adverse effects (54) 54
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1305) 1305
Japanese (34) 34
German (18) 18
French (11) 11
Spanish (7) 7
Italian (6) 6
Chinese (5) 5
Korean (1) 1
Norwegian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 07/2017, Volume 377, Issue 4, pp. 352 - 360
The addition of abiraterone, a drug that blocks endogenous androgen synthesis, to standard androgen-deprivation therapy in patients with newly diagnosed,... 
ANDROGEN-DEPRIVATION THERAPY | MEDICINE, GENERAL & INTERNAL | RECOMMENDATIONS | PLACEBO-CONTROLLED PHASE-3 | SURVIVAL ANALYSIS | CLINICAL-TRIALS | DOUBLE-BLIND | LEUPROLIDE ACETATE | DOCETAXEL | CHEMOTHERAPY | NEOADJUVANT | Prednisolone - adverse effects | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms - radiotherapy | Prednisolone - administration & dosage | Prostatic Neoplasms - surgery | Humans | Middle Aged | Abiraterone Acetate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Prostatic Neoplasms - mortality | Abiraterone Acetate - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Androgen Antagonists - therapeutic use | Adult | Aged | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Prostatic Neoplasms - drug therapy | Androgen suppression therapy | Usage | Prednisone | Research | Prostate cancer | Medical research | Prostate-specific antigen | Clinical trials | Metastasis | Patients | Cancer therapies | Metastases | Androgens | Chemotherapy | Pain | Castration | Medical prognosis | Hypokalemia | Death | Prostate | Abiraterone Acetate/administration & dosage | Prednisolone/administration & dosage | Androgen Antagonists/administration & dosage | Medical and Health Sciences | Medicin och hälsovetenskap | Neoplasm Metastasis/drug therapy | Steroid 17-alpha-Hydroxylase/antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols/adverse effects | Klinisk medicin | Clinical Medicine | Prostatic Neoplasms/drug therapy | Cancer and Oncology | Cancer och onkologi
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2015, Volume 33, Issue 4, pp. 332 - 339
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2013, Volume 368, Issue 14, pp. 1314 - 1325
Despite theoretical benefits of intermittent as compared with continuous androgen-deprivation therapy in patients with metastatic prostate cancer, intermittent... 
MEDICINE, GENERAL & INTERNAL | THERAPY | CLINICAL-TRIAL | FLUTAMIDE | QUALITY-OF-LIFE | SUPPRESSION | CARCINOMA | LEUPROLIDE | Confidence Intervals | Follow-Up Studies | Anilides - adverse effects | Humans | Middle Aged | Male | Gonadotropin-Releasing Hormone - analogs & derivatives | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis - drug therapy | Penile Erection - drug effects | Gonadotropin-Releasing Hormone - therapeutic use | Goserelin - adverse effects | Prostatic Neoplasms - drug therapy | Goserelin - administration & dosage | Prostatic Neoplasms - pathology | Tosyl Compounds - administration & dosage | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Tosyl Compounds - adverse effects | Anilides - administration & dosage | Survival Analysis | Quality of Life | Aged | Androgen Antagonists - administration & dosage | Nitriles - adverse effects | Usage | Care and treatment | Patient outcomes | Androgen suppression therapy | Drug therapy | Prostate cancer | Methods | Cancer | Statistical analysis | Mental disorders | Prostate-specific antigen | Clinical trials | Patients | Survival | Quality of life | Metastases | Androgens | Castration | Stem cells | Luteinizing hormone | Prostate
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2011, Volume 365, Issue 2, pp. 107 - 118
A course of androgen-deprivation therapy before and during radiotherapy prolonged 10-year survival by about 7% among men with intermediate-risk prostate... 
MEDICINE, GENERAL & INTERNAL | EXTERNAL-BEAM RADIOTHERAPY | THERAPY ONCOLOGY GROUP | DOSE-ESCALATION TRIAL | FOLLOW-UP | RADICAL PROSTATECTOMY | RANDOMIZED CONTROLLED-TRIAL | SUPPRESSION | HORMONAL-THERAPY | GROUP RTOG | RADIATION-THERAPY | Multivariate Analysis | Prostatic Neoplasms - radiotherapy | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Risk | Radiotherapy - adverse effects | Flutamide - adverse effects | Prostate - pathology | Leuprolide - administration & dosage | Aged, 80 and over | Gonadotropin-Releasing Hormone - therapeutic use | Goserelin - adverse effects | Gonadotropin-Releasing Hormone - agonists | Prostatic Neoplasms - drug therapy | Radiotherapy Dosage | Goserelin - administration & dosage | Prostatic Neoplasms - pathology | Survival Rate | Combined Modality Therapy | Erectile Dysfunction - etiology | Prostatic Neoplasms - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Androgen Antagonists - therapeutic use | Leuprolide - adverse effects | Aged | Flutamide - administration & dosage | Androgen Antagonists - adverse effects | Usage | Care and treatment | Hormone therapy | Diagnosis | Radiotherapy | Health aspects | Prostate cancer | Adenocarcinoma | Short term | Lymphatic system | Risk groups | Prostate-specific antigen | Mortality | Blood tests | Oncology | Metastasis | Radiation therapy | Phosphatase | Cancer therapies | Survival | Metastases | Androgens | Biopsy | Surgery | Prostate | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 6, Issue 6, p. CD009266
Journal Article
Fertility and Sterility, ISSN 0015-0282, 2014, Volume 101, Issue 6, pp. 1565 - 1573.e18
Journal Article
Fertility and Sterility, ISSN 0015-0282, 07/2019, Volume 112, Issue 1, pp. 98 - 104
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 5, pp. 421 - 432
Journal Article